Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron
While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to a manufacturing advantage that could unlock a “double-digit billion dollar opportunity” for Eli Lilly.Read more:
biospace.comBiotechnology